openFDA
Cure8 regulatory brief
Prednisone FDA label update (2026-07-31)
Medications
Prednisone
Corticosteroids
Steroids
Osteoporosis
Anemia
Regulatory Update
Adult patients
Why This Matters
Prednisone is a commonly used systemic steroid for short-term control of IBD flares; label updates affect dosing, warnings, and official approved uses that patients and clinicians rely on.
Who Should Pay Attention
Patients with ulcerative colitis or Crohn’s disease prescribed prednisone; caregivers; clinicians managing steroid therapy.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This is an FDA-linked DailyMed label update for prednisone (a systemic corticosteroid). The label lists approved indications, dosing guidance, and administration details that apply across many conditions, including inflammatory bowel diseases (Ulcerative colitis and Regional enteritis/Crohn’s disease).
It emphasizes individualized dosing, morning administration for single doses, gradual tapering after long-term therapy, and precautions such as avoiding abrupt withdrawal and considering dietary salt restriction.
The label also summarizes broad safety considerations and typical dosing ranges (5–60 mg daily as initial dosing, with higher doses for certain conditions) and mentions alternate-day therapy practices and adjustments during stress or exacerbations.
If you take prednisone or care for someone who does, the updated label is a reference for approved uses and dosing principles but is not a substitute for individualized medical advice from your clinician.
Keep In Mind
This is a DailyMed / FDA drug-label record (regulatory-document). It summarizes approved indications and dosing but is not individualized medical advice. Consult your clinician before changing therapy.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorPar Health USA, LLC
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 31, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Prednisone FDA label update (2026-07-13)
The FDA/DailyMed label defines approved uses and official dosing guidance for prednisone, a corticosteroid commonly used to treat moderate-to-severe inflammatory conditions including ulcerative colitis and regional...
SOLU-MEDROL FDA label update (2026-07-23)
This label is the official prescribing information for intravenous/intramuscular methylprednisolone (SOLU‑MEDROL). Corticosteroids are commonly used short‑term in IBD to treat moderate-to-severe flares when rapid...
Triamcinolone Acetonide FDA label update (2026-08-14)
The FDA label confirms triamcinolone acetonide injectable suspension is indicated for short-term use to manage flares in regional enteritis (Crohn’s disease) and ulcerative colitis and summarizes important safety and...